Stem Cell Clinic

New Cedars-Sinai Biomanufacturing Center to Spur Cell Therapies – Newswise

Newswise LOS ANGELES (Dec. 4, 2020) -- Cedars-Sinai has launched a center to manufacture the next generation of stem cell and gene therapies that will enable biomedical researchers, government medical programs, commercial entities and others to develop new biologic drugs and propel novel disease discoveries.

Biologic drugs are produced from living organisms or contain components of living organisms, such as cells, proteins or genes.

"TheCedars-Sinai Biomanufacturing Centerleverages our world-class stem-cell expertise, which already serves scores of clients, to provide a much-needed biomanufacturing facility in Southern California," saidClive Svendsen, PhD, executive director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute. "It is revolutionary by virtue of elevating regenerative medicine and its therapeutic possibilities to an entirely new level-repairing the human body."

Among the facility's initial clients is the Department of Defense, which has asked Cedars-Sinai scientists to manufacture banks of stem cells from multiple healthy volunteers for later use in repairing vascular injuries sustained by military personnel in combat.

The core technology of the Cedars-Sinai Biomanufacturing Center involves production of specialized cells known as induced pluripotent stem cells, or iPSCs. Scientists make iPSCs by genetically converting adult blood cells into cells that can self-renew indefinitely and differentiate into nearly any type of tissue. Each resulting cell carries the exact DNA of the person who donated the blood sample.

"IPSCs are powerful tools for understanding human disease and developing therapies," saidDhruv Sareen, PhD, executive director of the Biomanufacturing Center and director of the induced pluripotent stem cell facility at the Regenerative Medicine Institute. "These cells enable us to truly practiceprecision medicineby developing drug treatments tailored to the individual patient or groups of patients with similar genetic profiles."

The Biomanufacturing Center is designed to address a critical bottleneck in bringing cell- and gene-based therapies to the clinic. It will help relieve a nationwide shortage of facilities that can scale up production of cells for drug products that consistently meet current good manufacturing practice (cGMP) standards for strength, quality, and purity. These standards, set by the U.S. Food and Drug Administration, must be met when producing pharmaceuticals for use in humans.

To comply with the federal standards, the new Cedars-Sinai center features nine "clean rooms" that maintain rigorously aseptic conditions for handling of all biomaterials. These rooms are supported by staging areas, gowning rooms, quality control laboratories and storage rooms with ample freezers and liquid nitrogen tanks.

Other sections of the Biomanufacturing Center are devoted to research and production of iPSC cells, technology and development, training and collaboration laboratories, offices, and facilities maintenance equipment. Overall, the center occupies more than 28,000 square feet.

"Our expansive facilities provide complete, end-to-end support of biomedical research and development of cell therapies that are 'living medicines,'" said Sareen, assistant professor of Biomedical Sciences. "We enable our clients to explore and create new types of cells, use them to make discoveries about diseases and transform the resulting biomaterials into cGMP-compliant therapies for testing in clinical trials."

The recent grand opening of the Biomanufacturing Center, hosted on a virtual platform by Cedars-Sinai leadership, was attended by representatives of local and federal governments, biotechnology companies, funding organizations and other stakeholders. It was followed by another Cedars-Sinai virtual event, a "Symposium on Translational Medicine and Biomanufacturing," that drew world-renowned keynote speakers from academia and industry and hundreds of attendees to explore the latest developments in these fields.

"Our new Biomanufacturing Center reaffirms Cedars-Sinai's commitment to deliver the finest clinical care for our patients-and patients everywhere-by expanding the frontiers of medical science," said Svendsen, professor of Biomedical Sciences and Medicine.

Read more on the Cedars-Sinai Blog:What Are Induced Pluripotent Stem Cells?

More:
New Cedars-Sinai Biomanufacturing Center to Spur Cell Therapies - Newswise

Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease (SCD). The data from this clinical trial could provide proof-of-concept for MGTA-145, in combination with plerixafor, as the preferred mobilization regimen for patients with SCD. bluebird bios experience with plerixafor as a mobilization agent in sickle cell disease aligns with Magentas combination therapy approach, utilizing MGTA-145 plus plerixafor with potential to achieve safe, rapid and reliable mobilization of sufficient quantities of high-quality stem cells to improve outcomes associated with stem cell transplantation. Under the collaboration, the stem cells will be fully characterized, and Magenta will undertake preclinical studies to evaluate the ability of these cells to be gene corrected and engrafted in mouse models. The companies will co-fund the clinical trial and Magenta will retain all rights to its product candidate.

We are excited to build upon our leading position in the field of ex-vivo gene therapy and the promising clinical data with LentiGlobin in SCD with a collaboration focused on achieving improved stem cell mobilization, said Dave Davidson, M.D., chief medical officer, bluebird bio. In this initial study, we hope to establish whether the combination of plerixafor with MGTA-145 can generate appropriate CD34+ stem cells with a single round of mobilization. If successful, we hope to evaluate this novel mobilization regimen with LentiGlobin to make another step forward in the treatment of patients with SCD.

Achieving reliable and rapid stem cell mobilization and a simplified collection process can ensure the entire patient experience is optimal with respect to therapeutic outcome. The incorporation of bluebird bios experience in this area of treatment will be immensely valuable in further developing MGTA-145 plus plerixafor to address the remaining unmet needs in gene therapy approaches for diseases like sickle cell disease, said John Davis Jr., M.D., M.P.H., M.S., Head of Research & Development and Chief Medical Officer, Magenta Therapeutics. We look forward to collaborating with bluebird bio to evaluate MGTA-145 as the preferred mobilization option for people with sickle cell disease.

SCD is a serious, progressive and debilitating genetic disease caused by a mutation in the -globin gene that leads to the production of abnormal sickle hemoglobin (HbS), causing red blood cells (RBCs) to become sickled and fragile, resulting in chronic hemolytic anemia, vasculopathy and painful vaso-occlusive events (VOEs). For adults and children living with SCD, this means unpredictable episodes of excruciating pain due to vaso-occlusion as well as other acute complicationssuch as acute chest syndrome (ACS), stroke, and infections, which can contribute to early mortality in these patients.

Currently available mobilization drugs, including granulocyte-colony stimulating factor (G-CSF), a commonly used mobilization agent administered over the course of five to seven days in other transplant settings, is not used in sickle cell disease because it can trigger vaso-occlusive crises and even death in adults and adolescents. Plerixafor is used to mobilize a patients stem cells for collection prior to transplant and while an available treatment option, multiple cycles of apheresis and collection may sometimes be required to generate sufficient stem cells for gene therapy. Magenta is developing MGTA-145, in combination with plerixafor, to be the preferred mobilization regimen for rapid and reliable mobilization and collection of hematopoietic stem cells (HSCs) to improve stem cell transplantation outcomes in multiple disease areas, including genetic diseases such as sickle cell disease, as well as blood cancers and autoimmune diseases.

About Magenta Therapeutics MGTA-145

MGTA-145, in combination with plerixafor, has demonstrated, in a recently completed Phase 1 study in healthy volunteers, it can rapidly and reliably mobilize high numbers of functional stem cells in a single day, without the need for G-CSF. MGTA-145 works in combination with plerixafor to harness a physiological mechanism of stem cell mobilization to rapidly and reliably mobilize HSCs for collection and transplant across multiple indications.

Additionally, as shown in preclinical studies, stem cells mobilized with MGTA-145 can be efficiently gene-modified and are able to engraft, potentially allowing for safer and more efficient mobilization for gene therapy approaches to treat sickle cell disease and other genetic diseases.

Magenta completed its Phase 1 trial of MGTA-145 in healthy volunteers, demonstrating MGTA-145 was well tolerated and enables same-day dosing, mobilization and simplified collection of sufficient stem cells for transplant, meeting all primary and secondary endpoints.

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, were developing gene and cell therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, were working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. Were putting our care and expertise to work across a spectrum of disorders: cerebral adrenoleukodystrophy, sickle cell disease, -thalassemia and multiple myeloma, using gene and cell therapy technologies including gene addition, and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

LentiGlobin and bluebird bio are trademarks of bluebird bio, Inc.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with autoimmune diseases, genetic diseases and blood cancers. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant world to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit http://www.magentatx.com.

Follow Magenta on Twitter: @magentatx.

Forward-Looking Statement

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as may, will, could, should, expects, intends, plans, anticipates, believes, estimates, predicts, projects, seeks, endeavour, potential, continue or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption Risk Factors in Magentas Annual Report on Form 10-K filed on March 3, 2020, and in bluebird bios Annual Report on Form 10-K filed on February 18, 2020, as updated by each companys most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta and bluebird bio believe that the expectations reflected in the forward-looking statements are reasonable, neither Magenta nor bluebird bio can guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta or bluebird bio, nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. Neither Magenta nor bluebird undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Continue reading here:
Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta's MGTA-145 for Mobilizing and Collecting...

Global Single-cell Analysis Market Research Report 2020-2026 Featuring Major Players and Companies to Watch in the Future – PRNewswire

DUBLIN, Dec. 1, 2020 /PRNewswire/ -- The "Single-cell Analysis Market by Product, Cell Type, Technique, End User, and by Geography - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Single-cell Analysis Market is predicted to grow at a CAGR of ~17.1%. The market is predicted to reach $2005 million in 2026 from $763.4 million in 2020.

The information collected from this analysis is significant for cancer research for the discovery of tumor cells and genetic diagnosis. The factors such as advanced technology in products of single-cell analysis, increasing preference for customized medicine and rapidly increasing various chronic diseases such as cancer, which fuel the demand for the single-cell analysis market. However, the expensive products in the single-cell analysis are restraining market growth.

Single-cell analysis is the examination & study of proteins, study of small molecules, and other cells at the single-cell level. This analysis allows the study of variations of cell-to-cell in the group of cells. The objective of the single-cell analysis is to gain insight into the mechanisms of cellular functionality, which requires an understanding of each of the cellular components, including protein content, DNA, and RNA, as well as the cellular metabolites.

In the product based segmentation consumables segment is expected to have the largest share in the market. The reasons for the demand for consumables products are regularly purchasing the consumables compared to the instruments and the significant usage of consumables in the research and genetic exploration and segregation of RNA and DNA.

Based on cell type segmentation, the human cell segment is having the largest share in the market. The human cell is greatly used in the research laboratories due to the rising incidence of infectious diseases in the elderly population and the high investments in stem cell research.

On the bases of technique, the next-generation sequencing segment is expected to have the largest share in the market due to the increasing chronic diseases and next-generation sequencing allowing researchers to perform various applications.

Further, based on end-user segmentation, the academic and research laboratories segment is expected to have the largest share in the market. The increasing number of colleges and universities of medical and high investments in life science research are the factors accelerating the demand for single-cell analysis.

Moreover, based on the geography Asia Pacific region is playing a vital role in the market share compared to other regions due to rising number of patients in countries such as China and India, growing investments in the research and development in this field and outsourcing of drug discovery services to the Asia Pacific region. In addition, North America is the second-largest contributor to the market due to the high expenditure in the research and development and increased scope for stem cell research in this region.

The single-cell analysis market is expanding globally due to the increasingly advanced technology in the single-cell analysis products. The major factors accelerating the single-cell analysis market include rapidly increasing chronic diseases and cancer cases all over the world, increasing biotechnology & biopharmaceutical industries, and life science research. Although, due to high competition, the persistence of new entrants and small players is difficult in the market, and this is a challenge for market growth. The emerging markets in Asia are the future opportunities for the market.

The key market competitors in the market are Becton, Dickinson and Company, Danaher Corporatio, Merck Millipore, Qiagen N.V., Thermo Fisher Scientific, Inc, General Electric Company, BARCO, Promega Corporation, Shanghai Goodview Electronics, Fluidigm Corporation, Agilent Technologies, Inc, Nanostring Technologies, Inc., Tecan Group Ltd, Sartorius AG, LUMINEX CORPORATION, Takara Bio Inc., Takara Bio Inc., Fluxion Biosciences and Menarini Silicon Biosystems.

Moreover, the single-cell analysis has the largest scope in cancer research for the detection of the various tumor cells, preimplantation, and genetic diagnosis as the drastic increase in the cancer cases globally. The government is also supporting financially for cell-based research.

Key Topics Covered:

1. Executive Summary

2. Industry Outlook

3. Market Snapshot

3.1. Market Definition

3.2. Market Outlook

3.3. PEST Analysis

3.4. Porter Five Forces

3.5. Related Markets

4. Market characteristics

4.1. Market Evolution

4.2. Market Trends and Impact

4.3. Advantages/Disadvantages of Market

4.4. Regulatory Impact

4.5. Market Offerings

4.6. Market Segmentation

4.7. Market Dynamics

4.8. DRO - Impact Analysis

5. Technique: Market Size & Analysis

5.1. Overview

5.2. Consumables

5.2.1. Beads

5.2.2. Microplates

5.2.3. Reagents

5.2.4. Assay Kits

5.2.5. Other Consumables

5.3. Instruments

5.3.1. Flow Cytometers

5.3.2. NGS Systems

5.3.3. PCR Instruments

5.3.4. Spectrophotometers

5.3.5. Microscopes

5.3.6. Cell Counters

5.3.7. HCS Systems

5.3.8. Microarrays

5.3.9. Other Instruments

6. Cell Type: Market Size & Analysis

6.1. Overview

6.2. Human Cells

6.3. Animal Cells

6.4. Microbial Cells

7. Technique: Market Size & Analysis

7.1. Overview

7.2. Flow Cytometry

7.3. Next-generation Sequencing

7.4. Polymerase Chain Reaction

7.5. Microscopy

7.6. Mass Spectrometry

7.7. Other Techniques

8. End User: Market Size & Analysis

8.1. Overview

8.2. Academic & Research Laboratories

8.3. Biotechnology & Pharmaceutical Companies

8.4. Hospitals & Diagnostic Laboratories

8.5. Cell Banks & IVF Centers

9. Geography: Market Size & Analysis

9.1. Overview

9.2. North America

9.3. Europe

9.4. Asia Pacific

9.5. Rest of the World

10. Competitive Landscape

10.1. Competitor Comparison Analysis

10.2. Market Developments

10.3. Mergers and Acquisitions, Legal, Awards, Partnerships

10.4. Product Launches and execution

11. Vendor Profiles

11.1. Becton, Dickinson and Company

11.2. Danaher Corporation

11.3. Merck Millipore.

11.4. Qiagen N.V.

11.5. Thermo Fisher Scientific, Inc

11.6. General Electric Company

11.7. BARCO

11.8. Promega Corporation

11.9. Shanghai Goodview Electronics

12. Companies to Watch

12.1. Fluidigm Corporation

12.2. Agilent Technologies, Inc

12.3. Nanostring Technologies, Inc.

12.4. Tecan Group Ltd

12.5. Sartorius AG

12.6. LUMINEX CORPORATION

12.7. Takara Bio Inc.

12.8. Fluxion Biosciences

12.9. Menarini Silicon Biosystems

Companies Mentioned

Becton

Continued here:
Global Single-cell Analysis Market Research Report 2020-2026 Featuring Major Players and Companies to Watch in the Future - PRNewswire

Cell Therapy Technologies Market | Extensive Information on a Plethora of Aspects Related to the Growth of the Market – BioSpace

The cell therapy technologies market is expected to gain immense growth opportunities through the forecast period of 2019-2029 owing to the rising influence of cell therapies across the life sciences sector. The overwhelming need for novel and enhanced therapies for a variety of diseases and disorders may bring extensive growth prospects for the cell therapy technologies market during the forecast period.

The increased funding by the government may also prove to be a great growth prospect for the cell therapy technologies market. The precision medicine sector is evolving at a rapid rate across the globe. In this, a patient is given personalized treatment and is useful in making more accurate decisions. Thus, this factor may boost the growth of the cell therapy technologies market.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6943

Cellular therapy is the transplantation of human cells to replace cells or tissues. This therapy can be used for treating various diseases and disorders. The evolution of cell therapy technologies is bringing immense advancements across the sector. This therapy is used mainly for nervous system disorders and cancer. The growing cases of these diseases may further invite promising growth.

On the basis of product, the cell therapy technologies market can be segmented into consumables, cell processing equipment, single-use equipment, other equipment, and systems and software. Based on cell type, the cell therapy technologies market can be classified into stem cells, T-cells, and other cells. Cell therapy technology is utilized expansively in biopharmaceutical and biotechnology companies and CROs, and research institutes and cell banks.

The enhancements in cell therapy technology research through immense investments from various sectors may invite prominent growth prospects for the cell therapy technologies market.

This report has extensive information on a plethora of aspects related to the growth of the cell therapy technologies market. The L.E.A.P mechanism applied by the researchers enables a 360-degree view of the cell therapy technologies market. The CXOs derive the perfect information that allows them to chalk out their business strategy accordingly. This report also has scrutinized information about the novel coronavirus outbreak and its effect on the cell therapy technologies market.

Cell Therapy Technologies Market: Competitive Insights

The cell therapy technologies market is highly fragmented. Numerous players are involved in intense competition for gaining a prominent position among the end-users. The players are also involved in expansion activities through mergers and acquisitions. Some well-entrenched players in the cell therapy technologies market are Danaher Corporation, CellGenix GmbH, IxCells Biotechnology, Wilson Wolf Corporation, SIRION Biotech GmbH, Dickinson and Company, and FUJIFILM Irvine Scientific.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=6943&ltype=S

Cell Therapy Technologies Market: COVID-19 Impact

The COVID-19 impact may offer bright opportunities for the cell therapy technologies market to gain growth. The rising transmission of COVID-19 has led to rapid research and development activities in terms of an effective drug or vaccine. Cell-based research and technologies play an important role in the discovery of vaccines. Hence, this aspect may bring expansive growth prospects for the cell therapy technologies market.

Cell Therapy Technologies Market: Regional Prospects

The cell therapy technologies market in North America may gain a dominant position throughout the forecast period of 2019-2029. The maximizing research and development activities across the region for a good COVID-19 vaccine may bring profitable growth for the cell therapy technologies market. Robust healthcare expenditure, rising disposable income, and growing healthcare awareness may invite promising growth.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6943

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

See the original post here:
Cell Therapy Technologies Market | Extensive Information on a Plethora of Aspects Related to the Growth of the Market - BioSpace